George W. Sledge, Jr., MD, professor of medicine, Stanford University Medical Center, discusses the next steps for the phase III MONARH-2 trail following the positive interim analysis results presented during the 2019 European Society of Medical Oncology Congress.
Sarah Murawski, MPAS, discusses how telemedicine can impact the use of chimeric antigen receptor T-cell therapy in patients with cancer at the Association of Community Cancer Centers National Oncology Conference.
Zofia Piotrowska, MD, MHS, a medical oncologist at Massachusetts General Hospital and an instructor at Harvard Medical School, discusses the results from the phase III RELAY trial that investigated first-generation EGFR inhibitor erlotinib plus the VGEF-directed antibody ramucirumab in patients with EGFR-mutant lung cancer.<br />
Positive overall survival data from the phase II KATE-2 study were presented at the 2019 ESMO Annual Meeting. Leisha Emens, MD, shares the results.
Andre H. Goy, MD, predicts the future use of novel combinations for treatment of mantle cell lymphoma.
Jonathan Ledermann, MD, professor of oncology, UCL Cancer Institute, University College London, discusses the results of a subanalysis from the phase III ARIEL trial of rucaparib maintenance treatment for patients with recurrent ovarian carcinoma.
Mark Yarchoan, MD, explains his method for sequencing available treatment options for patients with hepatocellular carcinoma.<br />
Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, gives advice on using the JAK inhibitors ruxolitinib and fedratinib in the community setting for patients with intermediate-risk myelofibrosis.<br />
Kanti R. Rai, MD, professor of medicine, Northwell Health and Zucker School of Medicine at Hofstra University, explains the importance of attention to age when treating patients with chronic lymphocytic leukemia, which is a typically elderly patient population.
Thomas Marron, MD, discusses the rationale for investigating immunotherapy discontinuation in patients with melanoma.
Winston Tan, MD, discusses the emergence of novel agents for the treatment of patients with gastrointestinal stromal tumors, namely agents like avapritinib and ripretinib, which have shown promise in ongoing clinical trials.<br />
Ethan Basch, MD, MSc, recently received the Clinical Research Award from the Association of Community Cancer Centers during the 2019 National Oncology Conference. Basch explains the importance of receiving this award in light of his work around patient-reported outcomes for symptom monitoring in oncology.
Ali McBride, PharmD, MS, BCOP, discussed during the recent National Oncology Conference his goals for ACCC while serving as president, which include focusing on education, innovation, and compensation.<br />
Kerry Rogers, MD, discusses the rationale for evaluating ibrutinib in patients with hairy cell leukemia in the phase II trial.
Kathleen Moore, MD, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha–positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.
Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.
Pinkal Desai, MD, discusses the factors a practicing physician should consider when selecting an appropriate induction therapy for patients with acute myeloid leukemia.
William K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.
Heinz-Josef Lenz, MD, FACP, discusses the advances in immunotherapy for treatment of metastatic colorectal cancer.
Shaji Kumar, MD, discusses the shift in the treatment landscape for patients with multiple myeloma, and how more patients are eligible for stem cell transplantation because of new criteria.
Leonard G. Gomella, MD, discusses the factors that determine which patients with prostate cancer should undergo genetic testing.
Basem William, MD, discusses challenges in treating patients with cutaneous and peripheral T-cell lymphomas, as well as the challenges in conducting clinical trials in this patient population.
David Maloney, MD, PhD, medical director, Cellular Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, discusses the results of the ZUMA trial and how chimeric antigen receptor CAR T-cell therapy is changing the treatment landscape for non-Hodgkin lymphoma.
Laura Quan Man Chow, MD, FRCPC, discusses the rationale for evaluating ceritinib in patients with <em>ALK</em>-positive non–small cell lung cancer in the ASCEND-7 trial.
Daniel Catenacci, MD, discusses how he makes decisions with immunotherapeutic agents for the treatment of patients with gastroesophageal junction cancer. He says he bases his sequencing decisions on a number of factors.
Hope S. Rugo, MD, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting.
Winston Tan, MD, discusses the current treatment landscape for patients with thyroid cancer. He highlighted the importance of first determining if a patient with thyroid cancer has benign or malignant thyroid nodules, which can be identified with the use of diagnostic biopsies. He also discussed the standard-of-care treatment options for these different subtypes of patients once they are identified.
Simon Rule, MD, PhD, shares his thoughts on the FDA’s decision to grant zanubrutinib, a BTK inhibitor, priority review for the treatment of patients with mantle cell lymphoma. Should the drug be approved, it will be available for patients with MCL who have received at least 1 prior line of therapy.
Scott Kopetz, MD, PhD, explains how prognoses for patients with colorectal cancer differ based on whether their cancer is left-sided or right-sided and discusses how knowledge of these differences have led to the development of more agents to treat both groups of patients.
Lecia V. Sequist, MD, MPH, director, says that oncologists have developed a better understanding of what causes resistance to EGFR inhibitors in patients with non–small cell lung cancer through preclinical studies and biopsies. <em>MET</em> amplification was found to be one of the major causes of resistance to newer generation EGFR-targeted drugs.